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ABSTRACT 
Prosthetic vascular grafting is largely successful in patients undergoing surgical 
intervention for vascular diseases in medium and large caliber arteries (inner diameter >6 
mm). In small diameter arteries, however, prosthetic grafts are insufficiently non-
thrombogenic, and autologous vein grafting and endovascular stenting are considered to 
be standard treatments. However, up to one third of patients lack proper donor vessels due 
to donor site morbidities or severe vascular disease, and stenting fails to provide long-term 
patency. Further, patients with diabetes have not only increased risk for the development 
of cardiovascular diseases, but also have poorer outcomes following intervention. To meet 
this need, a small diameter tissue engineered vascular graft was developed to meet the 
needs of diabetic patients with vascular diseases. 
First, a biocompatible scaffold was created by decellularization of porcine renal arteries, 
then stabilizing the scaffolds using pentagalloyl glucose (PGG). PGG is a matrix-binding 
polyphenol previously shown to improve mechanical strength of decellularized tissues and 
to resist calcification and the accumulation of advanced glycation endproducts in STZ-
induced type I diabetic rats. Decellularization was assessed by histological analysis and 
isolation and quantification of DNA. 
Next, human adipose derived stem cells (hADSC) were differentiated in vitro to endothelial 
cells in media supplemented with vascular endothelial growth factor (VEGF) and insulin-
like growth factor (IGF-1). ADSC-derived endothelial cells and human aortic endothelial 
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cells (hAEC) were cultured in normal or high glucose for one week. Cells were assessed 
by immunofluorescence to confirm differentiation toward endothelial cells. Protein and 
RNA isolates were assessed for the expression of metabolic and inflammatory markers for 
diabetes to measure the resistance of differentiated hADSCs to a high glucose environment 
compared to hAEC. 
Finally, hAEC and human aortic adventitial fibroblasts (hAAFb) were drop-seeded onto 
the prepared scaffolds and conditioned in a custom-designed vascular bioreactor in normal 
or high glucose media for 4 weeks. Constructs explanted from the bioreactors were 
assessed for cell retention by Live/Dead Assay, scanning electron microscopy, and 
histology. Protein and RNA isolates were assessed for the same metabolic and 
inflammatory markers for diabetes. 
Histological analysis and DNA concentration showed complete decellularization of 
porcine renal arteries. A pilot study to assess the in vitro response of endothelial-
differentiated hADSCs to diabetic conditions was similar to that of hAEC. Decellularized 
arterial scaffolds seeded with fibroblasts and endothelial cells conditioned in a bioreactor 
retained some endothelial cells, but lacked fibroblasts after conditioning. 
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CHAPTER ONE: BACKGROUND AND REVIEW OF LITERATURE 
1.1 Cardiovascular Anatomy and Physiology 
1.1.1 Overview of the Cardiovascular System 
At its core, the cardiovascular system exists to conduct blood in a closed loop throughout 
the body. The center of this system is the heart, a four-chambered organ organized to create 
continuous, unidirectional flow of blood. In the pulmonary circuit, blood is pumped from 
the right ventricle through the pulmonary arteries to the lungs, wherein oxygen and carbon 
dioxide are exchanged with atmospheric gas, then the re-oxygenated blood returns through 
the left atrium. Once full, the atrium contracts to send blood into the left ventricle, which 
then pumps blood to the aorta, which has a series of branches coming off it to allow blood 
to travel throughout the body. At the periphery, nutrients, waste, gases, and hormones are 
exchanged in thin-walled capillaries. Blood then returns to through the venous system to 
the right atrium, and the cycle thus continues. 
1.1.2 The Vasculature 
Blood vessels are the conduits by which blood is conducted throughout the body. It is 
divided into three subtypes: arteries, veins, and capillaries. Additionally, smaller vessels 
called arterioles and venules to act as intermediate-sized vessels to connect capillaries to 
arteries and veins, respectively. The vessels are generally composed of endothelial and 
smooth muscle cells and extracellular matrix, primarily collagens, elastin, and 
glycosaminoglycans. Arteries and veins are multi-layered organs: the innermost, blood-
contacting layer is the tunica intima, also referred to as the endothelium, consists of a 
1
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monolayer of endothelial cells, a specialized type of epithelial cell, on top of a basement 
membrane. The tunica media is separated from the endothelium by an internal elastic 
lamina, forms the middle layer of blood vessels, and is composed of concentric layers of 
vascular smooth muscle cells (vSMC). The tunica externa is the outmost layer, and is 
separated from the media by external elastic lamina.26 It a loose connective tissue 
containing nerve endings and in larger vessels, a vasa vasorum26, a network of arterioles 
and capillaries that nourish the outermost parts of those vessels. Capillaries consist of a 
monolayer of endothelial cells on a basement membrane. 
Figure 1.1: The Cardiovascular System. The system is composed of the heart, the pulmonary circuit, which 
supplies the lungs, re-oxygenates blood, and removes waste carbon dioxide, the system circuit, which 
supplies blood to all other parts of the body besides the lungs. Oxygenated blood is depicted in red and 
deoxygenated blood is depicted in blue. [25] 
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Generally, arteries have thicker vessel walls and narrower lumens to compensate for greater 
mean pressure and flow rate. The largest arteries are those closest to the heart, and have 
inner diameters between 1 and 2.5 cm.25 These arteries have the highest elastin content, 
which allows for the arterial wall to stretch and recoil following a pulse of blood without 
permanent deformation while damping the pulsation generated by the cardiac rhythm; thus 
they are referred to as elastic arteries.31 Muscular arteries are slightly smaller than elastic 
arteries, with diameters between 3 mm and 1 cm.25 As the name suggests, these arteries 
have a proportionally thicker tunica media, which is stimulated by the endothelium or the 
nervous system to induce vasoconstriction or vasodilation in order to reduce to increase 
blood, respectively, to a given organ or tissue. Veins have much wider lumens and thinner 
walls than their companion arteries. This is because of the lower pressure experienced after 
flow through capillaries. This low pressure also means that blood flow is able to stop. To 
prevent blood from pooling in the peripheral veins, particularly in the limbs, veins have 
valves to prevent backflow, and deep veins lie next to skeletal muscles, which act to pump 
blood back toward the heart.25 
 
1.1.3 The Endothelium 
Endothelial cells are a specialized squamous epithelium form a 0.2-0.4 μm -thick 
monolayer of cells that line the luminal of surface of all vasculature and the heart10, and 
are key regulators of vascular wall homeostasis.38 With the exceptions of fenestrated 
endothelium in the hepatic and splenic vasculature, endothelial cells form a tight, 
selectively permeable barrier. Endothelial cells are highly dynamic and can change 
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phenotype based on homeostatic signaling. Under normal homeostatic conditions, 
endothelial cells form a barrier between the blood compartment and extravascular tissues, 
resist thrombogenesis, prevent immune cell extravasation, regulate vascular tone, and favor 
overturn of vascular extracellular matrix.26 
 
Figure 1.2: Activation of Endothelial Cells [26] 
 
Under various states of stress, including turbulent flow, hypertension, cytokines, 
complement activation, damage from hyperglycemia, hypoxia, acidosis and alkalosis, 
endothelial cells become activated.26 Activated endothelial cells become procoagulant, 
proinflammatory, and influence the underlying smooth muscle cells to contract and 
proliferate. These functions allow for hemostasis, inflammatory cell recruitment to combat 
infection, and intimal thickening to allow for vessel healing.26 This activated state is 
contrasted with endothelial dysfunction, a proinflammatory and procoagulant phenotype 
that forms the basis of various vascular disorders, including thrombosis, atherosclerosis, 
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and vascular lesions caused by hypertension and other disorder.24 Generally, endothelial 
dysfunction is a phenotypical alteration that leads to loss of homeostatic control and 
contributes to the pathogenesis of vascular diseases, including thrombosis, atherosclerosis, 
and vascular lesions seen in hypertensive patients.10,26,33 
 
1.1.3.1 Endothelial Regulation of Hemostasis 
Under normal conditions, endothelial cells express anti-platelet, anti-coagulation, and 
fibrinolytic factors that contribute to the total non-thrombogenicity of the tunica intima.38 
Endothelial cells constitutively express prostaglandin 2 (PGI2) and endothelial nitric oxide 
synthase (eNOS) to prevent adhesion of platelets to the vascular wall.10 PGI2 exerts a 
paracrine effect on platelets and nearby endothelial cells. In platelets, PGI2 inhibits 
thromboxane A2 (TXA2) synthesis, which is necessary for platelet activation and 
aggregation.10 eNOS catalyzes the reaction that produces nitric oxide (NO). NO inhibits P-
selectin expression and integrin glycoprotein IIb-IIIa activation in platelets, which are 
necessary for platelet aggregation and fibrinogen binding, respectively.10 Endothelial cells 
inhibit coagulation by releasing a variety of factors that inhibit the various parts of the 
coagulation cascade and fibrin clot formation. Finally, endothelial cells express tissue 
plasminogen factor (tPA), a fibrinolytic enzyme involved in clot dissolution.33 Upon 
activation, endothelial cells suppress their anti-thrombogenic phenotype and release tissue 
factor, an enzyme that catalyzes cleavage of Factors IX and X to aid in coagulation cascade 
progress.33 
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1.1.3.2 Endothelial Regulation of Immune Response 
In addition to inhibiting platelet adhesion, endothelial cells ensure that immune cells, 
especially leukocytes and monocytes, cannot bind to the vascular wall and enter the 
extravascular tissue. The endothelium does this by passively failing to produce the requisite 
chemoattractant and adhesive molecules necessary to mediate leukocyte recruitment.33 
Upon activation, endothelial cells produce cytokines that activate leukocytes, chemokines 
that recruit monocytes to the area of injury, and express surface adhesive molecules that 
allow immune cells to bind to the vascular wall. Early adhesion to the vascular wall is 
mediated by E-selectin, giving leukocytes low-affinity binding.6 Immune cells will then 
transiently “roll” along the vascular wall. Immune cells express integrins that bind to 
intracellular adhesion molecules (ICAMs) and vascular CAMs (VCAMs) expressed on the 
luminal surface of activated endothelial cells.6 Integrin-mediated binding allows for firm 
attachment to the vascular wall, and induces rapid cytoskeletal remodeling within the 
immune cells, which allows them to extravasate to the tissue bed by “squeezing” 
themselves through gaps between the endothelial cells in a process called diapedesis or 
transendothelial migration.6 
 
1.1.3.3 Endothelial Regulation of Vascular Tone 
Blood pressure is regulated by two key functions: cardiac output and peripheral 
resistance.26 Cardiac output is affected by stroke volume and heart rate. Peripheral 
resistance is primarily regulated by vascular tone at the arteriole level, and is balanced by 
levels of vasoconstrictors and vasodilators, many of which are produced by endothelial 
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cells.26 In addition to their roles as a platelet activation inhibitors, NO and PGI2 are potent 
vasodilators. Endothelial cells constitutively express eNOS, which continuously produced 
NO. Additional large levels of NO can be produced by and inducible nitric oxide synthase 
(iNOS), which is activated in macrophages, SMCs, and endothelial cells in response to 
cytokine signaling.33 PGI2 and TXA2 are vascular tone antagonists, inducing vasodilation 
and vasoconstriction, respectively.33 
 
During injury, the endothelium contributes to vasoconstriction to aid in prevention of blood 
loss. Endothelial cells are responsible for the production of endothelin-1 and angiotensin 
II by the actions of endothelin converting enzyme and angiotensin converting enzyme 
(ACE) on the cell membrane.33 Endothelin-1 is released abluminally to stimulate SMC 
contraction.10 Angiotensin II is the end product of the renin-angiotensin system that 
controls blood pressure by inducing vSMC contraction, stimulating aldosterone secretion 
by the adrenal glands to resorb filtered sodium, stimulating vasopressin secretion by the 
posterior pituitary gland to increase fluid retention in the kidneys, and inhibiting 
bradykinin, a vasodilator that induces NO and PGI2 release from endothelial cells.
10,26,33 
 
1.2 Cardiovascular Disease and Current Treatments 
1.2.1 Incidence of Cardiovascular Disease 
Cardiovascular diseases are the leading cause of morbidity and mortality in the world, and 
in the United States in 2011, accounted for 31.3% of deaths.27 These diseases include 
stroke, congenital heart disease, rhythm disorders, atherosclerosis, heart failure, valvular 
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disease, coronary artery disease, and peripheral artery disease.27 The focus of this review 
will be on macrovascular diseases, especially coronary, carotid, and peripheral artery 
diseases. Coronary artery disease (CAD) affects 6.2% (15 million) of the U.S. population, 
and is a significant risk factor in the development of heart failure and myocardial 
infarction.27 Peripheral artery disease (PAD) affects 3.5% (8.5 million) of the U.S. 
population27, and characterized by claudication, intermittent leg pain during physical 
activity. Left untreated, PAD can cause critical limb ischemia, which may require lower 
extremity amputation. 
 
1.2.2 Atherosclerosis 
Vascular pathologies are underpinned by two principle mechanisms, stenosis of the vessel 
that leads to obstruction of the vessel, and weakening of the vessel wall that can lead to 
dilation and eventual rupture.26 One of the mechanisms leading to vessel obstruction is 
arteriosclerosis, i.e. hardening of the arteries, which has three general manifestations: 1) 
arteriolosclerosis, which primarily affects small arteries and arterioles, 2) Mönckeberg 
medial sclerosis, dystrophic calcification in the tunica media of muscular arteries, and 3) 
atherosclerosis, deposition of a fatty plaque in the vessel wall.26 Atherosclerosis is the 
leading cause of morbidity and mortality in Western countries, and will be the focus of this 
review. 
 
The most common model for describing atherogenesis, the pathogenesis of atherosclerosis, 
is the response-to-injury hypothesis34, which “views atherosclerosis as a chronic 
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inflammatory and healing response of the arterial wall to endothelial injury.”26 First, 
endothelial cells experience chronic injury, particularly from hyperlipidemia and disturbed 
mechanical forces, leading to endothelial dysfunction that manifests in increased vascular 
permeability, leukocyte adhesion and extravasation, and thrombosis.34 Next, low density 
lipoprotein (LDL) and oxidized LDL begin to accumulate in the vascular wall. Monocytes 
then adhere, migrate into the vessel wall, and transform into macrophages. Smooth muscle 
cells also migrate into the intima in response to the vessel injury. Macrophages and SMCs 
begin accumulating deposited lipids, and macrophages transform into foam cells due to 
modified LDL ingested via scavenger receptors; this stage is referred to as a fatty 
streak.26,41 Macrophages are activated by uptaken cholesterol and free fatty acids (FFA) 
that interact with components of the inflammasome20 that enhances immune cell 
recruitment via cytokine release, increased lipid oxidation and oxidative stress via release 
of radical oxygen species (ROS), and SMC proliferation via growth factor release.26 
Activated T lymphocytes release interferon-γ (IFNγ), which activates macrophages, SMCs, 
and endothelial cells.20 Activated and proliferative intimal SMCs have a unique synthetic 
phenotype, in which they deposit ECM components, particularly collagen, which 
completes transformation of the fatty streak into a fibrofatty atheroma.26 This fibrofatty 
atheroma is commonly referred to as an atherosclerotic plaque. Cell necrosis within the 
plaque contributes to degeneration of the underlying intima, resulting in a vulnerable 
plaque that can lead to clinically relevant consequences.26 
 
10 
 
At the clinical stage, there are several important pathologic consequences. Acute changes 
in the surface of the plaque can lead to rupture, ulcerate, or erode, exposing the highly 
thrombotic interior of the plaque to the bloodstream and thus resulting in acute vessel 
occlusion.26,42 The plaque can weaken the surrounding vessel wall due to intimal ischemia 
and ECM degradation, which can induce aneurysm formation that may rupture. In small 
arteries, plaques can become large enough to occlude the vessel, resulting in downstream 
ischemia.4 At the clinical stage, there are several interventions, including pharmacotherapy, 
balloon angioplasty, stenting, and bypass graft surgery.7,36 
 
Table 1.1: Classification of atherosclerotic plaques based on morphology [42] 
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1.2.3 Endovascular Repair 
Since the introduction of balloon angioplasty in 197919, there have been several generations 
of technologies to improve the outcomes of percutaneous coronary interventions (PCI), 
including bare metal stents (BMS) and 1st and 2nd generations of drug-eluting stents (DES). 
Balloon angioplasty is now the first step in PCI, and involves catheterization in the 
coronary and expansion of a balloon that compresses the atherosclerotic plaque against the 
vascular wall. This immediately restores blood flow to the area of ischemia, but restenosis 
occurs in 50% of patients following balloon angioplasty.19 Restenosis is clinically defined 
as >50% vessel occlusion;19 due to the fourth power relation between tube diameter and 
conductance, this corresponds to a 94% reduction in flow rate. Endovascular surgeries 
cause localized trauma at the site of treatment and can lead to vessel wall spasm or 
thrombosis,27 and the vessel wall elastically recoils following balloon angioplasty.36 
 
To combat elastic recoil, bare metal stents were introduced in the late 1980s19, and stenting 
is now practiced in 90% of PCI surgeries.27 BMS improved restenosis rates to 20-30%19 at 
6-12 months27, but restenosis occurs due to a different pathology: intimal hyperplasia. 
Endothelial denudation and exposure of vSMCs due shear stress from blood flow causes 
SMCs to migrate to the intima, proliferate, and take on a synthetic phenotype similarly 
seen in atherosclerosis.19,27,36 Additionally, stenting requires exogenous administration of 
anti-thrombogenic and anti-platelets pharmaceuticals to address the presence of 
thrombogenic material exposed to the bloodstream.13 
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As an improvement to bare metal stents, manufacturers began coating stents in anti-
proliferative drugs, such as Sirolimus and Paclitaxel, to combat in-stent restenosis.13,19 
These stents improved restenosis rates to 5-15%19, but anti-proliferative therapies also slow 
healing of the endothelium, which is necessary to permanently halt SMC proliferation, and 
after the drug is fully released, DES resemble BMS and a “late catch-up phenomenon”19 is 
observed more than a year after initial revascularization. 
 
1.2.4 Vascular Replacement 
Synthetic grafts composed of hydrophobic polymers, such as poly (ethylene-terephthalate) 
(PET) and expanded polytetrafluoroethylene (ePTFE), affixed with metallic struts to resist 
kinking have largely been successful in large-diameter (>8 mm inner diameter) vascular 
grafting.8 Although these materials are not entirely non-thrombogenic, the shear forces in 
large-diameter arteries, such as the ascending and abdominal aorta, iliac, and femoral 
arteries, are great enough to inhibit thromboembolism formation; these grafts boast 90% 
patency rates 5 years after surgery.8 However, patency rates are as low as 39% at 5 years 
for the same materials in small-diameter vessels (<6 mm inner diameter), such as the 
coronary artery and arteries below the knee, compared to 74% in autografts.8 In addition 
to insufficient blood flow to overcome graft thrombogenicity, compliance mismatch 
between the graft and the native artery and flow disturbances contribute to intimal 
hyperplasia at the distal end of the graft.36 5-year patency rates are similar between 
synthetic and autologous grafts for medium-caliber arteries (6-8 mm inner diameter).8 
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The first successful attempt at vascular intervention was the use of an autologous 
saphenous vein graft for a femoropopliteal bypass in 1948.36 Autologous vessel grafting is 
now considered the gold standard in vascular intervention.8,36 The saphenous vein is the 
most commonly used autograft due to length and ease of access36, and the internal 
mammary and radial arteries are also commonly used.8 The saphenous vein, however, is 
considered an inferior choice, and has a 10-year patency rate of 50% due to the mechanical 
mismatch of a new high-flow environment that leads to aneurysm, intimal hyperplasia, and 
atherosclerosis in the graft.36 Internal mammary arteries, on the other hand, have 10-year 
patency rates greater than 90%. Unfortunately, one-third of patients lack sufficient donor 
grafts due donor site morbidity, prior vessel harvesting, or anatomical suitability.8 
 
1.2.5 The Need for a Tissue Engineered Vascular Graft 
Due to high rates of revision surgeries, insufficient long term patency, inadequate 
performance of synthetic grafts, and insufficient access to donor grafts, there is a need for 
an alternative solution for revascularization surgeries. With advances in material science 
and cell biology, tissue engineering has shown great promise to meet this need. The goal 
of developing a tissue engineered vascular graft is to mimic the properties and geometry of 
the native vessel being replaced. Ideally, such a graft would match mechanical strength and 
compliance, be non-toxic and non-immunogenic, be non-thrombogenic, be easy to handle 
and suture, have reasonable costs and batch consistency in manufacturing, and totally 
integrate with the host tissue, including the ability to grow when implanted in pediatric 
patients.8,27,36 
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1.3 Impact of Diabetes Mellitus in Cardiovascular Disease 
1.3.1 Characterization of Diabetes Mellitus 
Diabetes mellitus (DM) is a chronic metabolic disease characterized by dysregulation of 
blood glucose levels.29 DM generally falls into three categories. In type I diabetes, 
previously known as juvenile-onset diabetes because peak diagnosis age occurs in the mid-
teens, is the result of autoimmune attack on the β cells of the pancreatic islets, which are 
responsible for insulin secretion. This leads to the inability to mediate hyperglycemia, and 
thus patient survival requires regimented exogenous administration of insulin. Type I DM 
is the most severe form of diabetes and accounts for about 5% of diagnosed cases of 
diabetes.28 Type II DM, formerly known as adult-onset diabetes due to the later onset than 
type I DM, is typically brought on by progressive insulin resistance, insufficient production 
of insulin by the pancreatic islets, or both and represents 90 to 95% of diabetes cases.28 
Gestational diabetes is a form of glucose intolerance reported in 5 to 10% of pregnant 
women often diagnosed in the second or third trimester. Gestational diabetes has similar 
risk factors to those of type II DM, and can itself be a risk factor for gestational diabetes in 
future pregnancies or the development of type II diabetes.28 
 
Diagnosis of diabetes is based on four criteria: 1) fasting plasma glucose ≥126 mg/dL, 2) 
random plasma glucose ≥200 mg/dL in patients experiencing classic hyperglycemic signs, 
3) plasma glucose ≥200 mg/dL following an oral dose of 75 g glucose (oral glucose 
tolerance test, OGTT), and 4) glycated hemoglobin (HbA1C) ≥6.5%.23 The first, third, and 
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fourth tests are repeated to confirm diagnosis. Patients who do not exhibit outright diabetes 
can be identified as prediabetic, or having impaired glucose tolerance. The criteria for 
prediabetes are 1) fasting glucose between 100 and 125 mg/dL, 2) plasma glucose between 
140 and 199 mg/mL 2 hours after an OGTT, and 3) HbA1C between 5.7% and 6.4%.
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1.3.2 Incidence and Impact of Diabetes Mellitus 
In 2014, 29.1 million people of all ages in the United States had diabetes, accounting for 
9.3% of the population.28 This includes 8.1 million people with undiagnosed diabetes. A 
further 86 million Americans aged 20 years or older may have prediabetes.28 There are 387 
million people ages 20 to 79 worldwide are estimated to have diabetes in 2014, at 8.3% of 
the world population.17 This epidemic is expected to grow to 582 million (10% of the world 
population) by 2030.17 Diabetes caused 245 billion USD in direct and indirect costs in the 
United States in 201228, and 612 billion USD worldwide in 2014.17 
 
DM is one of the major risk factors for the development of cardiovascular diseases (CVD) 
and stroke. Patients with diabetes are at a 2- to 4- fold greater risk for developing coronary 
artery disease (CAD)27 and a 100-fold greater risk for developing peripheral 
atherosclerosis-induced gangrene, which requires amputation.23 While 8.5% of adults in 
the U.S. in 2012 had diagnosed DM,2 DM patients represented 27 and 30% of patients 
undergoing surgical repair for CAD and peripheral vascular disease (PVD), respectively.27 
Cardiovascular diseases include microangiopathies, particularly nephropathy, retinopathy, 
neuropathy, and impaired wound healing, and macroangiopathies, such as coronary artery 
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disease, cerebrovascular disease, and peripheral vascular disease.30 The pathogenesis of 
CVD in diabetic patients is complex and not yet fully understood, but four distinct 
mechanisms or pathways have been implicated: advanced glycation endproduct formation, 
oxidative stress and alteration of the polyol pathway, activation of protein kinase C, and 
increased hexosamine pathway activity.18,23,29 
 
1.3.3 Biochemical Mechanisms of Hyperglycemic Damage 
1.3.3.1 Advanced Glycation Endproduct Formation 
Advanced glycation endproducts (AGEs) are a heterogeneous group of molecules formed 
by non-enzymatic reaction between reducing sugars and amino acids.29 AGEs accumulate 
naturally during aging, but this process is accelerated in diabetic patients. Glycation occurs 
via the Maillard reaction, which begins with the spontaneous formation of a Schiff base 
between the carbonyl groups of glucose or other reducing sugars and a free amino acid.39 
The Schiff base can rearrange to form an Amadori product or fragment as a result of 
glycoxidation to form reactive intermediates, such as glyoxal (GO), methylglyoxal (MGO), 
or 3-deoxyglucosone.39 These reactive dicarbonyl precursors can also be produced by other 
glycolytic pathways or during lipid peroxidation. Amadori products finally undergo further 
structural changes via oxidation and degradation to irreversibly form AGEs39, and 
dicarbonyl precursors can form AGEs directly.23 AGE precursors not only alter 
intracellular proteins, but easily diffuse across the cell membrane, where they can modify 
extracellular matrix proteins and circulating blood proteins.39 The glycation of biological 
molecules by glucose and other sugars alters their function, leading to a wide array of 
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consequences. 
 
 
Figure 1.3: The Maillard Reaction leads to the formation of AGE production first by reversible 
interaction between the carbonyl group of a reducing sugar with amino groups of proteins to form 
a Schiff base. This is followed by glycoxidation of the sugar side chain to form a dicarbonyl or 
further rearrangement to form an Amadori product. Amadori products can undergo irreversible 
oxidation, dehydration, or degradation to form an AGE. Dicarbonyls can form AGEs directly. [30] 
 
First, glycation of intracellular proteins leads to increased proteosomal degradation, altered 
cell signaling, and altered gene expression, all of which can lead to aberrant cell function 
or cell death. AGEs can directly cross-link ECM proteins23, especially collagens.39 Cross-
linking of collagens type I and type IV in the vascular bed causes a decrease in vessel 
elasticity, thereby increasing wall shear stress, and decreasing endothelial cells adhesion to 
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the basement membrane, respectively, and thus contributes to endothelial dysfunction.40 
Further, ECM protein cross-linking increases proteolytic degradation and impairs matrix-
cell signaling.23,39 Finally, glycated circulating blood proteins induce pro-inflammatory 
signaling and oxidative stress via interaction with receptors for AGEs (RAGE) expressed 
by endothelial cells, vascular smooth muscle cells, and inflammatory cells (macrophages 
and T lymphocytes).23,39 
 
The AGE-RAGE signaling axis results in a variety of effects. Most of these effects are 
thought to occur via NAPDH oxidase (NOX) -dependent activation of NF-κB, leads to an 
inflammatory response.23 Endothelial activation from AGE-RAGE signaling includes 
increased expression of adhesion molecules (selectins, VCAM-1, ICAM-1), which allows 
for increased recruitment of leukocytes and monocytes, and increased expression of 
endothelin-1 and decreased eNOS, causing increased vasoconstriction and impaired 
vasodilation, respectively, that contributes to hypertension.4,29 Signaling from glycated 
LDL and albumin stimulates expression of inflammatory cytokines (TNF-α, IL-1, IL-6) 
that increase activation of pro-inflammatory cells, MMPS-1, -2, -3, and -13, and 
chemokines that increase inflammatory cell recruitment.29 Further, RAGE is upregulated 
in the cells of DM, thus further accelerating the damaging effects of AGE formation.21 This 
milieu of events lead to increased inflammatory cell recruitment, extravasation to the 
vascular bed, uptake of glycated and glycoxidized LDLs, which have significantly 
increased levels in diabetic patients, via scavenger receptors, foam cell formation, and 
growth of fatty streaks.18,29 These factors contribute to the accelerated atherogenesis seen 
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in diabetic patients. 
 
Figure 1.4: The AGE-RAGE signaling axis induces an oxidative stress and pro-inflammatory environment 
which contributes to accelerated atherogenesis in diabetic patients [30] 
 
1.3.3.2 Oxidative Stress and the Polyol Pathway 
Oxidative stress in DM is induced by concomitant increased production of reactive oxygen 
species (ROS) and decreased activity of molecular antioxidants in concert with increased 
blood glucose. The most damaging effects of diabetic oxidative stress are seen in cells that 
are unable to regulate intracellular glucose levels and generate high levels of ROS during 
hyperglycemia, especially endothelial cells, mesangial cells of the kidney, neurons and 
neuroglia, and pancreatic β cells.29 ROS are produced as normal byproducts of cellular 
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metabolism by the mitochondrial respiratory chain and various oxidative enzymes by cells 
of the innate immune system as a defense against pathogens. Although the production of 
ROS is a natural process, their presence can lead to pathologic effects if unchecked. These 
include lipid peroxidation, leading to membrane degradation, protein modifications that 
lead to misfolding or impaired function and increased proteosomal breakdown, and single- 
and double-stranded breaks in DNA, which can result in mutations.23 These effects are 
collectively referred to as oxidative stress. To combat these effects, cells have numerous 
mechanisms to scavenge free radicals. These include antioxidant molecules that block free 
radical formation or scavenge free radicals, such as retinol, β-carotene, tocopherols, 
ascorbic acid, and glutathione, and scavenger enzymes, including superoxide dismutase, 
catalase, and glutathione peroxidase.23 Should an imbalance between ROS production and 
scavenging activity arise, oxidative stress ensues. 
 
During DM, excess glucose oxidized in the tricarboxylic acid cycle increases the amount 
of electron donors pushed through the electron transport chain of the mitochondrial 
membrane.4,29 This results in a “back-up” in electron transfer and subsequent donation of 
electrons to molecular oxygen and the formation of superoxide (O2°
-), a potent ROS 
normally degraded to peroxide by superoxide dismutases (SOD).23 Further, aldose 
reductase, an enzyme which has the normal function of reducing aldehydes to less toxic 
alcohols, metabolizes excess intracellular glucose to sorbitol, a polyol.23 This process 
requires consumption of NADPH, which is a critical cofactor for restoring reduced 
glutathione (GSH), a key intracellular antioxidant.10 These are keys examples of how DM 
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induces an imbalance between ROS production and scavenging.  
 
1.3.3.3 PKC Activation 
PKC activation due to increased intracellular glucose leads to a variety of altered signaling 
pathways, resulting in downregulation of endothelial nitric oxide synthase (eNOS), 
upregulation of endothelin-1, transforming growth factor β (TGF-β), and plasminogen 
activator inhibitor-1 (PAI-1), and activation of NF-κB and NADPH oxidase (NOX) by 
vascular endothelial growth factor (VEGF), among others.29 These lead to decreased 
vasodilation and hypertension (eNOS and endothelin-1, respectively), proinflammatory 
signaling (NF-κB), oxidative stress (NOX), increased recruitment of monocytes (VCAMs, 
ICAMs), and decreased fibrinolysis (PAI-1).4,29 This signaling cascade, leads to 
accelerated atherogenesis in diabetic patients, thus contributing to the increased rate of 
macroangiopathies in those patients. 
 
1.3.3.4 The Hexosamine Pathway 
In the first steps of glycolysis, glucose is converted to glucose-6-phosphate, and then into 
fructose-6-phosphate.24 From there, the glycolytic pathway can continue, or fructose-6-
phosphate can be diverted in the hexosamine signaling pathway, in which some fructose-
6-phosphate is enzymatically converted into N-acetylglucosamine, which participates in 
O-linked glycosylation of serine and threonine residues as a part of signal cascade 
propagation.4,29, In DM, excess glucosamine is produced and in particular, 
overmodification of the transcription factor Sp1 leads to upregulation of TGFβ-1 and PAI-
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1 expression.4,29 These exacerbate fibrosis in the vascular walls of diabetic patients. 
 
 
Figure 1.5: Summary of the effects of diabetes on atherogenesis [4] 
 
1.4 Strategies for Vascular Tissue Engineering 
In tissue engineering, there are two generalized approaches: top-down, in which a synthetic 
or biological material that acts as a template is seeded with cells that then reorganize 
themselves and the scaffold, and bottom-up, or self-assembly. The scaffold-based, top-
down approach to tissue engineering follows the schema of isolating cells from a patient, 
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expanding and possibly manipulating those cells in vitro, seeding those cells onto a 
scaffold, conditioning the scaffolds in a bioreactor, then implanting the new tissue 
engineered construct into the patient.36 
 
 
Figure 1.6: Scaffold-Based Approach to Tissue Engineering. [36] 
 
1.4.1 Decellularized Tissue as a Biological Scaffold 
The extracellular matrix (ECM) provides an ideal scaffold for tissue engineering.3 
Decellularized tissues maintain similar architecture, mechanical properties, and bioactivity 
to native tissues. This allows for cell in-growth, matched tissue compliance, and proper 
cell signaling, respectively.32 Further, the use of fully decellularized xenogeneic tissue 
takes advantage of the readily-available source of tissues from slaughtered animals while 
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providing a scaffold that is composed of only extracellular matrix proteins, which are 
highly conserved in evolution, and thus do not elicit and immune response.32 There is 
however, a careful balance to be achieved when using decellularized tissues as scaffolds: 
complete removal of immunogenic antigens and integrity of the ECM.3,32,36 
 
There are a variety of techniques to decellularize tissues. These techniques vary based on 
the decellularization agents employed, physical methods of decellularization, and the 
manner in which the decellularization agents are applied.10 Decellularization agents include 
hypertonic and hypotonic solutions, acid and bases, detergents, enzymes, and chelating 
agents.10 Physical parameters include temperature, force (such as agitation or sonication), 
pressure and pressure gradients across the tissue, electric current and electroporation, 
perfusion of tissues, and use of supercritical fluids.10 Decellularization techniques used in 
this project will be reviewed. 
 
Water is the most readily available method for inducing hypotonic shock in cells. The lack 
of salts outside of the cell causes a massive influx of water into the cell due to osmotic 
imbalance, causing cells to lyse. However, this technique poorly removes cell debris after 
lysis.10 Acidic and basic solutions increase solubility of cell cytoplasmic components, as 
well as aid in denaturation of proteins and degradation of nucleic acids; however acids and 
bases similarly catalyze the degradation of collagen and collagen crosslinks and 
glycosaminoglycans in the extracellular matrix.10 This leads to poorer mechanical strength 
in tissues decellularized by strong bases.10 Peracetic acid acts with a dual mechanism of 
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decellularization by removal of residual nucleic acids and sterilizing the decellularized 
tissue.10 
 
1.4.2 Polyphenol Stabilization of Decellularized Tissue Scaffolds 
Pentagalloyl glucose (PGG) is a polyphenol comprised of a central glucose moiety linked 
to five gallic acid units (Figure 1.7).9,44 PGG has been shown to exhibit a variety of 
beneficial effects. First, PGG has a high affinity for proline-rich proteins, and PGG-bound 
elastin and collagen have been shown to resist enzymatic degradation.14,38 PGG is an 
antioxidant and can act as a free radical sink.1 PGG has also been shown to be anti-
inflammatory by inhibiting cytokines such as TNFα and IL-6, possibly through inactivation 
of the transcription factor NFκB.44 
 
 
Figure 1.7: Steric Configurations and 3D structure of Pentagalloyl Glucose. [44] 
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Previously, PGG has been shown to mitigate the effects of diabetic damage on 
decellularized arterial and valvular scaffolds by reducing the accumulation of AGEs, 
reducing matrix calcification, and decreased inflammatory response of PGG-treated 
scaffolds when implanted in streptozotocin-induced type I diabetic rats compared to normal 
rats.9 
 
1.4.3 Cell Sources for Tissue Engineered Vascular Grafts 
Cells of the native vasculature consist of endothelial cells, smooth muscle cells, and 
fibroblasts. Efforts to seed decellularized grafts are centered on reconstituting these cell 
populations. While useful for research purposes, there are many drawbacks to using 
autologous primary vascular cells. Above all, isolation requires blood vessel biopsy, which 
adds additional complication, time, and possibly lack of availability in patients requiring 
revascularization surgery.32 As an alternative to vascular cells, progenitor, adult stem cells 
from bone marrow or adipose, embryonic stem cells, or induced pluripotent stem cells are 
all under exploration.32 
 
Of particular interest are adipose-derived stem cells (ADSCs), a multipotent cell population 
capable of differentiating into a variety of cell types, including each of the cell types in the 
blood vessel wall.6,12 Compared to other sources of adult stem cells, ADSCs are easily 
isolated in large quantities with minimally invasive biopsy.6 ADSCs and other 
mesenchymal stem cells (MSCs) have garnered attention for their immunomodulatory 
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phenotype.16 ADSCs and MSCs are able to suppress inflammation in part by suppressing 
activation and proliferation of immune cells.23 
 
1.4.4 Mechanical Conditioning 
One of the weaknesses of modern cell biology is the reliance on static cell culture on tissue 
culture plastic. While is provides a convenient way to expand and study cells, it is a wholly 
unrealistic method for replicating in vivo processes. To greater increase understanding of 
basic cell biology, and to bridge the gap between the bench and the bedside, improved cell 
culture techniques are needed, and bioreactors offer a method to do so. 
 
Native vasculature experiences circumferential stretch from blood pulsation and shear 
stresses from blood flow. It has been shown that those forces effect smooth muscle cell and 
endothelial cell biology, as well as the differentiation of adipose-derived stem cells toward 
those lineages.15,17 Further, bioreactors provide a method for even seeding of scaffolds, 
increase tissue oxygenation, and remove waste from cells more readily. 
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CHAPTER TWO: PROJECT MOTIVATION, SPECIFIC AIMS, AND 
SIGNIFICANCE 
 
Current therapeutic approaches for treatment of small-diameter vascular diseases, such as 
PCI and CABG, offer significant improvements in patient health and lifespan, but require 
continuous anti-coagulation therapies and present the risk of subsequent risk of restenosis 
or other cardiovascular events, particularly in diabetic patients. Tissue engineering 
promises to address these needs, but most approaches fail to address the most common co-
morbidities and pathologies in the patients in need of those technologies. To address both 
of these needs, a tissue engineered vascular graft is being developed that can withstand 
damage in a diabetic environment. 
 
The overall goal of this project is 1) assess the effect of hyperglycemia on adipose-derived 
stem cells differentiated toward an endothelial phenotype by measuring metabolic and 
inflammatory markers for diabetes and 2) perform a feasibility study for the conditioning 
of cell-seeded decellularized porcine renal arteries in a vascular bioreactor. In the long 
term, these seeded scaffolds will be implanted in situ in the abdominal aorta of healthy and 
diabetic rats, and this project will contribute to the in vitro develop of the grafts. 
 
Aim I: To develop a decellularized and polyphenol-stabilized porcine renal artery scaffold 
 
Porcine renal artery segments were isolated by dissection of kidneys sourced from a local 
abattoir, decellularized using a previously validated protocol13, then treated with 
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pentagalloyl glucose, a polyphenol previously shown to increase scaffold resistance to 
diabetic conditions9. Efficacy of decellularization was assessed by histological analysis and 
DNA content. 
 
Aim II: To assess the in vitro resistance of endothelial-differentiated adipose derived stem 
cells to diabetic conditions 
 
Human Adipose-Derived Stem Cells (hADSC) were differentiated for three weeks in an 
endothelial differentiation medium. hADSC and Human Aortic Endothelial Cells (hAEC) 
were cultured for one week in normal or high glucose media. Differentiation of hADSC 
was assessed by immunofluorescence, and protein expression of diabetic markers was 
assessed by Western Blot and Cytokine Array. 
 
Aim III: To reseed decellularized scaffolds, condition in a vascular bioreactor, and assess 
resistance to diabetic conditions 
 
Decellularized arterial scaffolds were dynamically seeded in a vascular seeding chamber 
or statically-seeded by pipetting with hAEC on the luminal surface and Human Aortic 
Adventitial Fibroblasts (hAAFb) on the adventitial surface, then conditioned in a vascular 
bioreactor in normal or high glucose media for four weeks. Cellularity of the TEVG was 
assessed by Live/Dead Cell Viability Assay and Scanning Electron Microscopy. 
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CHAPTER THREE: PREPARATION AND CHARACTERIZATION OF 
DECELLULARIZED AND PENTAGALLOYL GLUCOSE-STABILIZED 
PORCINE RENAL ARTERY SCAFFOLDS 
 
3.1 Approach and Rationale: 
Decellularized xenogeneic tissues offer a readily available source of highly biocompatible 
and bioactive scaffolds that match the native architecture, biochemistry, and mechanical 
properties as native arteries. Porcine renal arteries have previously been demonstrated to 
provide a consistent source of small diameter arteries that could be re-seeded and 
implantation in situ in rat abdominal aortas for in vivo testing of a TEVG14. That 
decellularization technique was replicated, and this chapter shows that technique and the 
verification done on every round of scaffold preparation to demonstrate complete 
decellularization. 
 
3.2 Materials and Methods: 
3.2.1 Scaffold Preparation 
Kidneys were collected from a local abbatoir (Snow Creek Meat Processing, Seneca, SC) 
and transported on ice until further processing. Excess adipose tissue was trimmed off and 
the renal artery of each kidney was identified. The arteries were clamped and adherent 
extravascular tissue was removed by blunt dissection until the tertiary branches of the renal 
artery were exposed. The arteries were then cut to select pieces that were 1-3 mm inner 
diameter, ≥1.5 cm in length, and free of holes or small branching arteries or arterioles. At 
this stage, some fresh artery pieces were collected and transferred to 10% phosphate-
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buffered formalin (Fisher Scientific) for histological analysis or frozen and stored at -80°C 
to await digestion and isolation of DNA. 
 
 
 
Figure 3.1: Dissection Process for Porcine Kidneys. Extrarenal connective tissue (A) was first removed. 
The primary renal artery is isolated (B), then non-vascular tissue is removed. This is done by grasping 
extravascular tissue, which is loosely attached to the artery adventitia, and pulling it away from the artery. 
Large pieces of extravascular tissue, kidney tissue, and adipose tissue are trimmed with scissors. Once renal 
artery branches too small for use (those with an inner diameter <1 mm or length <1 cm) are exposed, the 
entire hierarchical structure is trimmed off. Individual portions are measured to select for the most optimal 
scaffold pieces (C), those with inner diameter 1-2 mm and length >1.5 cm, and then cut away from the rest 
of the branches. 
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3.2.2 Decellularization of Porcine Renal Arteries 
The selected fresh arteries were then immersed in distilled and deionized water (ddH2O) 
overnight at 4°C. This and al subsequent steps were performed at a ratio of 3 arteries per 
100 mL of solution. Following overnight immersion in hypotonic solution, the artery pieces 
were transferred to 0.1 M NaOH (sodium hydroxide, Fisher Scientific) solution in ddH2O 
and agitated on a shake plate at 37°C for 3 hours. The arteries were washed for 30 min each 
in several changes of ddH2O at room temperature while shaking until the decanted wash 
solution reached pH<8. The arteries washed once with phosphate-buffered saline solution 
(PBS, Corning), then immersed in fresh PBS and stored again overnight at 4°C. 
 
3.2.3 Sterilization and Stabilization of Decellularized Arteries: 
Following overnight storage, the arteries were transferred to sterile containers and 
immersed in 0.22 μm-filtered 0.1 M peracetic acid (Sigma Aldrich) in PBS, pH =7.4, and 
shaken at room temperature for 2 hours in the dark. The arteries were then rinsed in 3 
changes of sterile PBS for 30 min each. 
 
The arteries were then washed in 0.22 μm-filtered 1M PGG (N.V. Ajinomoto OmniChem 
S.A.), 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Fisher 
Scientific), 8 mM sodium chloride (Fisher Scientific), 20% isopropanol (Acros Organics), 
in ddH2O, pH=5.5, shaking, overnight at room temperature in the dark. The arteries were 
then rinsed, shaking, in three changes of PBS for 15 min each, one change for 2 hours, then 
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three changes for 15 min each. The arteries were then stored in sterile PBS with 1% 
Pen/Strep (10,000 IU/mL Penicillin, 10,000 μg/mL Streptomycin, Mediatech, Inc.) at 4°C 
for up to two months. 
 
3.2.4 Histological Analysis  
Upon completion of decellularization, arteries were immersed in 10% phosphate-buffered 
formalin at a ratio of greater than 100 mL formalin per cm3 of tissue for 24 to 48 hours. 
Next, fresh and decellularized arteries were paraffin-embedded with a Tissue-Tek VIP 
Tissue Processor (Sakura Finetek USA, Inc.). Samples were embedded in paraffin blocks, 
cut into 5 μm-thickness sections, fixed onto histology slides (Premiere) and heated at 56°C 
overnight to fix the artery sections to the slides. 
 
Slides were de-paraffinized in xylenes (Fisher Scientific), dehydrated in progressive 
alcohols, and hydrated to distilled water, then stained with 1) 4',6-diamidino-2-
phenylindole (VectaShield Hard Set Mounting Medium with DAPI, Vector Labs, Inc.) for 
the presence of nuclei (figure), 2) hematoxylin and eosin for nuclei and extracellular matrix 
structure, or 3) Masson’s Trichrome (Poly Scientific R&D Corp) for collagen, muscle, and 
nuclei. 
 
3.2.5 Quantitative and Qualitative Assessment of DNA Content 
To assess DNA content, fresh and decellularized arteries were first frozen and stored at -
80°C, then lyophilized at -40°C and 0.01 mbar for 24 hours. Samples were weighed to 
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establish dry weight for DNA concentration comparison and to assure samples were <25 
mg. DNA was isolated using a DNeasy Blood and Tissue® Kit (Qiagen) following the 
manufacturer’s instructions for animal tissue extraction. DNA concentration was assessed 
by Quant-iT PicoGreen® dsDNA Assay Kit (Invitrogen) following the manufacturer’s 
instructions. Samples and standards were assayed in triplicate. 
 
A 1% agarose (BM Biomedicals, LLC) gel was prepared in 0.5X TBE Buffer (90 mM 
Tris(hydroxymethyl)aminomethane, EMD Chemicals, 90 mM Boric Acid, Fisher 
Scientific, and 1.6 mM Ethylenediaminetetracetic acid (EDTA), Sigma Aldrich, in ddH2O, 
pH=8.3 ), microwaved until the agarose melted, then 1.3 μm Ethidium Bromide (Bio-Rad 
Laboratories) was added when the gel solution cooled to <60°C. The gel was poured into 
a Gel Caster (Bio-Rad Laboratories) with a 20-well comb for 30 min. Sample and blank 
(nuclease-free water, Acros Organics) dilutions were prepared in a 1:5 dilution in 6X 
Blue/Orange Loading Dye (Promega)  and DNA standard (100 μg/mL 1kb DNA ladder, 
Promega) was prepared in a 1:6 dilution in loading dye. 20 μL ladder, blank, or sample 
were loaded per well. The gel was immersed in 1X TBE Buffer and run at 100V and 3 mA 
for 75 min. The gel was imaged in a ChemiDoc XRS+ Gel Imager (Bio-Rad Laboratories) 
according to the manufacturer’s instructions. 
 
3.3 Results and Discussion 
3.3.1 Gross Analysis 
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Color change in the scaffolds was notable between fresh and decellularized arteries. 
Immediately after dissection, arteries appeared a light red, but not quite pink. Following 
overnight immersion in water, the arteries were mostly white with a pink tinge. Following 
NaOH treatment, the arteries appeared pale white with a yellow tinge and are slightly 
translucent. Following peracetic acid treatment, the arteries appeared pale, opaque white. 
 
3.3.2 Histological Analysis 
Adequate decellularization of porcine renal arteries was first assessed by the absence of 
cells or cell nuclei and by the preservation of extracellular matrix proteins and morphology. 
DAPI binds strongly to nucleic acids, and thus can be used to visualize nuclei location and 
shape. It is often used as a counterstain against other fluorescent staining techniques. In 
this context, it provides a quick and simple method for visually detecting the presence of 
nuclei and their location. The use of this technique becomes particularly useful when 
examining tissues that appear decellularized by gross analysis, but histology or DNA 
extraction show that decellularization was not complete. In such tissues, nuclei may appear 
diffuse, indicating cells and nuclei have lysed but not adequately removed, or may only 
appear in the middle of a layer of tissue, indicating that decellularization agents 
insufficiently penetrated the tissue. Staining was compared against freshly dissected 
arteries that were rinsed lightly in PBS to remove adhering clots, then immediately fixed 
in formalin, then paraffin-embedded following 24 hours. 
36 
 
 
Figure 3.2: DAPI staining of fresh and decellularized arteries. Fresh arteries show abundant cellularity 
in the intimal, medial, and adventitial layers of the arteries (A and B). Decellularized arteries show a total 
lack of cellularity in all three layers. (C and D). Images were acquired under a blue filter (A and C). To show 
placement of cells with respect to tissue structure, bright light was added in addition to a blue filter (B and 
D). All images taken at 200X magnification. 
 
Histological analysis indicates full removal of cells in the decellularized arteries. DAPI 
staining (figure) demonstrates a total lack of cells in any layer of the tissue. In fact, it is not 
possible to see any tissue on the slide without white light (figure). Hematoxylin and Eosin 
staining demonstrate that 1) cells were removed and 2) the architecture of the extracellular 
matrix remained intact, as evidenced by the “holes” in which cells would have resided. 
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Figure 3.3: H&E and Masson’s Trichrome staining of fresh and decellularized tissue. Hematoxylin is a 
dark blue to violet basic stain that binds to negatively charged structures, such as nucleic acids, and eosin is 
a pink to red acidic stain that binds to positively charged structures, such as proteins. The more concentrated 
the protein concentration, the stronger eosin staining appears, and thus ECM proteins in isolation appear light 
pink and intact cells appear darker pink to red. Masson’s Trichrome is a three-colored stain that stains 
collagen blue, muscle red, and nuclei dark red to black. Fresh arteries (A and B) demonstrate intact 
endothelium, densely populated medial layers, and loose, collagen-heavy adventitia. Decellularized arteries 
show a lack of stained nuclei and white spaces where cell have been removed (C) and show removal of 
smooth muscle cells from all layers of the tunica media (D). Additionally, decellularized arteries demonstrate 
retention of the ultrastructure of the tissue. A, B, and C were taken at 200X magnification. D was imaged at 
100X magnification. 
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3.3.3 DNA Content 
Analysis of DNA content indicates sufficient removal of immunogenic cellular material. 
DNA content has become established in the use of decellularized organs as scaffolds for 
tissue engineering, as DNA itself is highly immunogenic and it can also serve as a proxy 
for the presence of other potentially immunogenic materials in the ECM (Badylak, 2011). 
Generally, a tissue can be considered to be non-immunogenic if the decellularized organ 
meets the following criteria: 1) contains less than 50 ng of DNA per mg of tissue (dry 
weight), 2) any residual DNA is less than 300 base pairs in length, and 3) lack visible 
nuclear material by conventional histological analysis, namely DAPI and hematoxylin and 
eosin (Badylak, 2011). In these scaffolds, a 94.3% reduction of DNA concentration was 
achieved, and the concentration was significantly level less than the threshold level of 50 
ng DNA/mg tissue dry weight. Further, gel electrophoresis with ethidium bromide staining 
failed to show any visible sign of DNA content in the decellularized tissue. 
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Figure 3.4: Quantification of DNA isolated from fresh and decellularized arteries. The concentration of 
DNA isolate from fresh and decellularized arteries was determined by Picogreen® Assay. The total mass of 
DNA in each sample was calculated from the assayed concentration and compared to the dry weight after 
lyophilization of the sample tissue. 
 
 
Figure 3.5: Agarose gel electrophoresis on DNA isolated from fresh and decellularized arteries. Lane 
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1 is a Promega 1 kb DNA Ladder. Lane 2 is a blank. Lanes 3-10 are DNA isolated from fresh porcine renal 
artery branches. Lanes 11 through 18 are DNA isolated from decellularized porcine renal arteries. The 
molecular weight guide is measured against the ladder and is units of base pairs. 
 
3.5 Conclusions: 
Previous use of this technique showed by immunostaining that α-galactosidase, a powerful 
porcine immunogen, was removed upon decellularization, subsequent cytocompatibility 
testing demonstrated safety of these grafts14]. Removal of cells was demonstrated in 
tandem by histological analysis that showed a total lack of cells and by 94.3% reduction in 
DNA content of the scaffolds. Taken with previous validation studies, these arteries should 
not elicit an immune response in in vitro re-seeding experiments (Chapter 5) or in animal 
model testing. 
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CHAPTER FOUR: ASSESSING DIFFERENTIATION AND IN VITRO 
DIABETES RESISTANCE OF ADIPOSE-DERIVED STEM CELL-DERIVED 
ENDOTHELIAL CELLS 
 
4.1 Approach and Rationale: 
Arguably the most important cell for generating a tissue engineered vascular graft because 
a confluent layer of endothelial cells is currently the only known truly non-thrombogenic 
surface.8 However, endothelial cells are particularly prone to diabetic complications 
because of their inability to control intracellular glucose flux during hyperglycemia30 and 
thus will likely be prone to contribute to failure of a TEVG if implanted in a diabetic 
patient. To control inflammation and modulate the immune response, adipose derived stem 
cells differentiated toward and endothelial fate offer a promising choice. To assess the 
resistance of differentiated ADSCs to diabetic conditions, ADSCs will be differentiated, 
then cultured in normal or high glucose media. Markers for endothelial differentiation, 
metabolic pathway markers (mTOR and PPARγ), oxidative stress (NOX1), and 
inflammation (NFκB, TNFα, IFNγ, and IL12) were analyzed to determine the diabetes 
resistance potential of differentiated ADSCs compared to endothelial cells. 
 
4.2 Materials and Methods: 
4.2.1 hADSC and hAEC Culture 
Human adipose-derived stem cells (hADSC p3, Invitrogen) were plated at 5,000 cells/cm2 
in MesenPRO RSTM Medium (Life Technologies) and cultured at 37°C and 5% CO2. 
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MesenPRO RSTM Medium was prepared from MesenPRO RSTM Basal Medium (Life 
Technologies) with 2% MesenPRO RSTM Growth Supplement (Life Technologies), 2 mM 
L-glutamine (Life Technologies), and 1% Pen/Strep. Media was changed 24 hours 
following plating and every 48 hours subsequently. hADSCs were subcultured at 80% sub-
confluence, approximately every 3 days. At passage 6, hADSCs were plated at 3,500 
cells/cm2 in endothelial differentiation medium and cultured for 21 days with media 
changes every 3 days. Endothelial differentiation medium was prepared as follows: 
Dulbecco’s Modified Eagle Medium (DMEM) with sodium pyruvate, L-glutamine, and 1 
g/L glucose (Corning) with 2% Fetal Bovine Serum (FBS, Atlanta Biologicals), 1% 
Pen/Strep, 0.5 ng/mL VEGF, and 20 ng/mL Insulin-like Growth Factor 1 IGF-1. 
 
Human Aortic Endothelial Cells (hAEC p4, Lonza) were plated at 5,000 cells/cm2 in 
Endothelial Growth Medium 2 (EGMTM-2, Lonza) and cultured at 37°C and 5% CO2. 
EGMTM-2 was prepared from Endothelial Basal Medium (EBMTM-2, Lonza) and EGMTM-
2 SingleQuots Kit (Lonza). Media was changed 24 hours following plating and hAEC were 
subcultured at 90% sub-confluence, approximately every 4 days. 
 
At passage 6, hADSC-derived endothelial cells (hADSC-EC) and hAEC were passaged 
and plated onto well plates in normal or high glucose media at 3,500 cells/cm2. Normal 
media was prepared from DMEM with 2% FBS and 1% Pen/Strep to yield 5.5 mM glucose 
and high glucose media was prepared from DMEM with 2% FBS, 1% Pen/Strep, and 4.5 
43 
 
g/L D-Glucose Monohydrate (EMD Chemicals) to yield 30 mM glucose. Cells were 
cultured for 1 week at 37°C with 5% CO2 and media was changed daily. 
 
4.2.2 Immunofluorescence 
To assess differentiation of adipose-derived stem cells to an endothelial cells, hADSC-EC 
were stained with markers for endothelial cells: CD31, Von Willebrand Factor (vWF), and 
VEGFR2. First, media was removed and cells were fixed in 4% paraformaldehyde in PBS, 
pH=6.9 for 20 min, permeabilized with 0.3% Triton X-100 (Alfa-Aesar) in PBS for 10 
min, then blocked with 5.0% Bovine Serum Albumin (BSA, Rockland, Inc.) and 0.5% 
Triton X-100 in PBS for 2 hours. Cells were incubated in primary antibody solution, diluted 
in diluted blocking solution (2.5% BSA, 0.25% Triton in PBS), overnight at 4°C slowly 
shaking: 10 μg/mL Rb Anti-CD31 IgG (Abcam ab28364), 20 μg/mL Rb Anti-vWF IgG 
(Abcam ab9378), or 1 μg/mL Rb Anti-VEGFR2 IgG (Abcam ab39638). Cells incubated in 
secondary antibody solution (4 μL/mL in diluted blocking solution, AlexaFluor 488 Do 
Anti-Rb IgG, Thermo Scientific) and counterstained for nuclei with 1.43 μM DAPI in PBS 
for 5 min at room temperature and in the dark. Cells were rinsed with PBS between each 
step. Cells were imaged using company. 
 
4.2.3 Assessment of Protein Expression - Western Blot and Cytokine Array Panel 
Cells were lysed by direct application of RIPA Buffer to the well plate and disruption with 
a cell scraper. RIPA Buffer was prepared from 50 mM Tris-HCl (EMD Chemicals), 150 
mM Sodium Chloride (Fisher Scientific), 1 mM EDTA (Sigma Aldrich), 1% Triton X-100 
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(Alfa Aesar), 1% Sodium Deoxycholate (Fisher Scientific), 0.1 Sodium Dodecyl Sulfate 
(Avantor Performance Materials), and 0.1% Protease Inhibitor Cocktail (Sigma Aldrich P-
8340) in ddH2O, pH=7.4. Cell lysates were centrifuged at 12,000 xG for 15 min at 4°C and 
the supernatant transferred and stored at -20°C until use. Protein concentrations were 
assessed by Bicinchoninic Acid Assay (BCA Assay, Thermo Scientific) according to the 
manufacturer’s directions using the plate method. Samples and standards were assayed in 
triplicate. 
 
4.2.3.1 Western Blot 
To prepare samples for electrophoresis, the volume of each sample necessary to yield 15 
μg/lane was calculated. Samples were diluted in 1X non-reducing buffer (company) with 
concentration β-Mercaptoethanol (β-ME, company) and boiled 5 minutes to denature the 
proteins. Electrophoresis and transfer were run for 90 min at 100V each. The membranes 
were blocked overnight at 4°C in 2% nonfat dry milk (NFDM, Bio-Rad Laboratories) in 
Tris buffer, then blotted overnight at 4°C with 2.00 μg/mL Rb anti-mTOR (Abcam 
ab51089), 1.00 μg/mL Mo anti-PPARγ (Abcam ab41928), 0.500 μg/mL Rb anti-NOX1 
(Abcam ab55831), or 0.621 μg/mL Rb anti-NFκB (Abcam ab32360) in diluted blocking 
solution. Primary antibody detection was achieved using a Mo/Rb secondary antibody and 
reagents from a BM Chemiluminescence Western Blotting Kit (Roche). The blots were 
imaged using a ChemiDoc XRS+ Gel Imager (Bio-Rad Laboratories) and analyzed by 
relative band intensity (densitometry) and molecular weight using the supplied software 
(ImageLab, Bio-Rad Laboratories). 
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4.2.3.2 Cytokine Array Panel 
The relative expression of the cytokines TNFα, IL12, and IFNγ were assessed using a 
Human Cytokine Panel Array A by R&D Systems (Bio-Techne) following the 
manufacturer’s directions with minor exceptions. Briefly, protein samples were obtained 
from cell lysates as described above. Four nitrocellulose membranes containing anti-
cytokine antibodies printed in duplicate were blocked for 1 hour at room temperature. 
Samples were diluted to 100 μg protein in 1.5 mL supplied buffer, mixed with 15 μL 
antibody cocktail, and incubated 1 hour at room temperature. The blocking buffer was 
aspirated and each membrane was incubated in sample-antibody solution overnight at 4°C. 
The membranes were washed with water and dried, then rinsed in wash buffer. The 
membranes were incubated in Streptavidin-HRP solution for 30 min at room temperature, 
washed in wash buffer, dried, and developed in Chemi Reagent Mix. The membranes were 
imaged the same as for Western Blotting. 
 
4.3 Results and Discussion 
4.3.1 Differentiation of Adipose Derived Stem Cells 
Differentiated hADSC showed positive immunofluorescence when stained with antibodies 
for CD31, VEGFR2, and vWF (Figure 4.1A, 4.1B, and 4.1C, respectively). The 
fluorescent brightness of differentiated hADSC was lower than that of hAEC stained for 
the same markers (Figure 4.1). Differentiated hADSC demonstrate a spindle-shaped 
A B C 
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morphology unchanged from undifferentiated hADSC, whereas endothelial cells display a 
round, flattened morphology. 
 
Figure 4.1: Immunofluorescent Staining of Differentiated hADSC and hAEC. Cells were stained for 
endothelial markers CD31 (A and D), VEGFR2 (B and E), and vWF (C and F). Images were taken at 200X 
magnification. 
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4.3.2 Analysis of Protein Expression 
Both hAEC and differentiated hADSC show a trend toward increased mTOR expression 
in diabetic conditions compared to normal. Similarly, hAEC and differentiated hADSC 
show a trend toward increased NFκB in diabetic versus normal conditions, but was much 
greater for endothelial cells. Additionally, blots for NOX1 and PPARγ did not yield 
identifiable bands (Figures A3 and A4). The experiment could not be performed again due 
to insufficient protein samples (see Table A1 for protein yields and use in experiments). 
 
Figure 4.2: Analysis of Protein Expression in Differentiated hADSC and hAEC in Normal or High 
Glucose by Western Blot. AN = hADSC in normal media; AD = hADSC in high glucose media (diabetic); 
EN = hAEC in normal media; ED = hAEC in diabetic media; ADSC had a higher baseline expression of 
mTOR over hAEC (3.3 v. 1.6 Relative Densitometry Units, RDU) and had a greater fold-increase in 
expression in diabetic conditions (2.6-fold greater v. 3.8-fold). ADSC had a greater baseline expression of 
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NFκB (4.6 v. 3.9 RDU), but had a smaller fold-increase in expression in diabetic conditions (1.4-fold v. 4.7-
fold). N=3, pooled, 15 μg protein per lane for all samples. 
 
Cytokine expression analysis yielded mixed results. Most of the markers on the panel 
yielded no expression in any of the samples. This may be due to insufficient protein levels 
(see Table A1) or insufficient exposure to high glucose conditions to cause an 
inflammatory response. The markers that did show expression are shown in Figure 4.3. 
CCL2, CXCL1, and CXCL10 are chemokines that recruit inflammatory cells, particularly 
neutrophils and macrophages, to the site of inflammation. These markers are by ADSCs in 
high glucose conditions, CCL2 is also expressed in normal conditions. CD40 and ICAM-
1 are a receptor for TNF and an adhesion molecule expressed on the cell surface for 
inflammatory cell attachment, respectively, and are expressed by differentiated ADSCs in 
high glucose. IL-18 and IL32α are activators of T cells and macrophages, respectively, and 
showed the greatest levels of expression in both differentiated ADSCs and hAECs in 
normal and high glucose. In differentiated ADSCs, the expression is increased in high 
glucose, but the trend is reversed in hAECs. Interleukins 4 and 10 are anti-inflammatory 
cytokines that promote M2 macrophage polarization and block the activation of NFκB, 
respectively. These are both expressed by differentiated ADSCs in both normal and high 
glucose conditions. 
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Figure 4.3: Analysis of Cytokine Expression in Differentiated sADSC and hAEC in Normal or High 
Glucose. CCL2 = Chemokine Ligand 2; CD40 = Tumor Necrosis Factor Receptor 5; CXCL1 = Chemokine 
Ligand 1; CXCL10 = Chemokine Ligand 10; ICAM-1 = Intracellular Adhesion Molecule 1; IL18 = 
Interleukin 18; IL32a = Interleukin 32a; IL4 = Interleukin 4; IL10 = Interleukin 10; N=3, pooled and 100 μg 
protein were used per membrane. 
 
4.4 Conclusions 
Endothelial-differentiated ADSCs showed differentiation toward an endothelial 
phenotype, but with some limitations. Immunofluorescence was weak in differentiated 
ADSCs, and cell morphology did not resemble endothelial cells. This confirms previous 
differentiation studies in ADSCs, which showed that full differentiation of ADSCs toward 
endothelium required shear conditioning in order for cells to uptake LDL or form tubules 
in hydrogels.15 ADSCs demonstrated a similar response in altered expression of metabolic 
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markers and certain inflammatory markers to endothelial cells, but showed strong 
resistance to NFκB upregulation in diabetic conditions. Promisingly, differentiated ADSCs 
showed expression of interleukins 4 and 10, which shows promise that even after 
differentiation, these cells can modulate the phenotype of immune cells. In all, 
differentiated ADSCs demonstrate similar or improved resistance to inflammation or 
metabolic distress, depending on the marker, to endothelial cells in high glucose conditions. 
Although this did not support the hypothesis that differentiated ADSCs could mitigate the 
inflammatory response induced by high glucose conditions, this does show that ADSCs 
are a viable alternative to endothelial cells in vascular tissue engineering. 
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CHAPTER FIVE: RECELLULARIZATION AND BIOREACTOR 
CONDITIONING TO ASSESS IN VITRO RESISTANCE OF TISSUE 
ENGINEERED VASCULAR GRAFTS TO HIGH GLUCOSE TO HIGH 
GLUCOSE CONDITIONS 
 
5.1 Approach and Rationale 
In addition to 2D culture, to assess the in vitro diabetes-resistance of differentiated ADSCs, 
cell need to be conditioned and tested in an environment that mimics the in vivo 
environment. Shear stress has been shown to alter endothelial cell phenotype8, and has been 
shown to be a requirement for full phenotypic differentiation of ADSCs15. This additional 
component should not only prepare TEVG for implantation, but should also provide data 
that corresponds more closely to eventual data from animal models. To accomplish this, a 
vascular bioreactor designed in the Biocompatibility and Tissue Regeneration Laboratory 
was used to condition the vessels. In addition, a vascular seeding chamber was used to 
dynamically seed cells onto decellularized and PGG-stabilized porcine renal artery 
scaffolds. 
 
5.2 Materials and Methods 
 5.2.1 hAEC and hAAFb Culture 
Human Aortic Endothelial Cells (hAEC p4, Lonza) were plated at 5,000 cells/cm2 in 
Endothelial Growth Medium 2 (EGMTM-2, Lonza) and cultured at 37°C and 5% CO2. 
EGMTM-2 was prepared from Endothelial Basal Medium (EBMTM-2, Lonza) and EGMTM-
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2 SingleQuot Kit (Lonza). Media was changed 24 hours following plating and hAEC were 
subcultured at 90% sub-confluence, approximately every 4 days. 
 
Human Aortic Adventitial Fibroblasts (hAAFb p2, Lonza) were plated at 3,500 cells/cm2 
in Stromal Cell Growth Medium (SCGMTM, Lonza) and cultured at 37°C and 5% CO2. 
SCGMTM was prepared from Stromal Cell Basal Medium (SCBMTM, Lonza) and SCGMTM 
SingleQuot Kit (Lonza). Media was changed 24 hours following plating and hAAFb were 
subcultured at 80% sub-confluence, approximately every 4 days. 
 
5.2.2 Dynamic Seeding of Decellularized Arterial Scaffolds 
To neutralize any remaining PGG resident in the decellularized and PGG-stabilized 
scaffolds, scaffolds were immersed in a neutralizing solution of 50% DMEM and 50% FBS 
and incubated for 24 hours at 37°C. Scaffolds were then rinsed once with PBS. Arterial 
scaffolds were then cannulated by affixing each end of the scaffold onto 1/16” barbed 
quick-turn couplings and secured to the coupling with 6-0 sutures. Cannulated scaffolds 
were then stored in PBS + 1% Pen/Strep at 4°C until use (<24 hours). 
 
Components of an in-house designed vascular seeding chamber (Figure 5.1) and parts to 
cannulate decellularized arterial scaffolds were individually cleaned, dried, packaged in 
sterilization pouches, and autoclaved. In a sterile environment set up in a laminar flow 
hood, the components were unpackaged and the chambers were partially assembled. 10/32” 
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x 1 1/2” bolts were fed through a rail, a silicone membrane, and the body of each seeding 
chamber. The Luer fitting were closed off using quick-turn plug caps. 
 
 
Figure 5.1: Solidworks Drawing of Vascular Seeding Chambers. Vascular scaffolds are fixed in the center 
of the chamber between the middle Luers. The left and right Luers can be used to seed the adventitia or to 
change media. All 6 ports are capped before removing the chamber from the sterile field. Silicone membranes 
on each side allow for gas exchange. 
 
A fibroblast seeding solution was prepared by passaging hAAFb p6 and re-suspending at 
50,000 cells/mL in DMEM + 10% FBS + 1% Pen/Strep. Two scaffolds were affixed to 
each seeding chamber and interconnected with 1/16” inner diameter tubing and quick-turn 
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barbed fittings. Seeding chamber assembly was then completed by addition of the bottom 
rail and nuts. To seed each pair of scaffolds with fibroblasts, one plug cap was removed 
from each side of a seeding chamber, and the chamber (on the adventitial side of the 
scaffolds) was flooded with ~50 mL fibroblast solution until air bubbles were removed. 
The plug caps were then placed back on the exposed Luer fittings on the seeding chambers. 
 
The chambers were affixed to a rotary seeder controlled by a LabView program. The 
seeding chambers were rotated in 10 s intervals at 2 rpm (a 1/3 turn) for 8 hours. An 
endothelial cells medium was prepared from hAEC p6 in the same fashion as was the 
fibroblast solution. The lumen of the scaffolds were flooded with ~ l mL of endothelial 
solution, and the scaffolds were placed back on the rotary seeder overnight. 
 
5.2.3 Bioreactor Setup 
Components of an in-house designed vascular bioreactor (Figure 5.2) were cleaned, dried, 
packaged in sterilization pouches, and autoclaved or ethylene oxide sterilized. In a sterile 
environment, the components were unpackaged and the bioreactor was partially assembled 
by assembling all of the components except for the lid. The rotary-seeded scaffolds were 
removed from the sterile seeding chambers, transferred to the bioreactor chamber, and 
fitted to the quick fittings via 1/16” tubing and barbed quick-turn couplings (Figure 5.3). 
Five seeded scaffolds were placed in each bioreactor. The chamber was filled with ~500 
mL normal or high glucose media (DMEM + 10% FBS + 1% Pen/Strep with 1 g/L glucose 
or DMEM + 10% FBS + 1% Pen/Strep with 5.5 g/L glucose, respectively) and the lid was 
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secured. The media reservoirs were filled with additional media (~1000 mL) and the caps 
were secured. The bioreactor was transferred to an incubator and affixed to a peristaltic 
pump. The pump was set to 50 mL/min and the incubator was at 37°C and 5% CO2 (Figure 
5.4). The flow rate was increased by 50 mL/min every 12 hours until the final flow rate 
was 250 mL/min. Seeded scaffolds were conditioned for 4 weeks, with one change media 
at 2 weeks. 
 
 
Figure 2.2: The Vascular Bioreactor. Flow originates from a pulsatile pump (A) that generates flow by 
rolling a metal bar across the tubing. The media flows through a media reservoir with a filter cap that allows 
for oxygen exchange (B). A manifold (C) splits the current evenly into 5 flow streams to flow through the 
lumen of each arterial scaffold (D), then re-converges them in a second manifold (E). The flow then passes 
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through the main chamber of the bioreactor to perfuse to the adventitia of the scaffolds and out the top. A 
second media reservoir (F, not shown) holds additional media and acts as a compliance chamber that dampens 
the pulsation generated by the pump. 
 
 
 
Figure 5.3: Cannulated Decellularized Arterial Scaffolds in the Vascular Bioreactor. The vascular 
bioreactor was first designed for the conditioning of re-seeded decellularized bovine carotid and mammary 
arteries, which have internal diameters of 5-6 mm and total length of ~9 cm. The vascular bioreactor was 
adapted using a smaller barbed quick-turn coupling and tubing to accommodate for the length. 
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Figure 5.4: Normal and High Glucose Vascular Bioreactors in an Incubator Just Prior to Removal 
 
5.2.4 Assessment of Dynamically-Seeded TEVG Cellularity Following Bioreactor 
Conditioning 
Upon removal from the bioreactor, two TEVG from each bioreactor were cut in half and 
each half was snap-frozen in liquid nitrogen and stored at -80°C. Three TEVG from each 
bioreactor had a 1 mm-long piece cut off for assessing cellularity via Lead/Dead Cell 
Viability Assay (Invitrogen). Briefly, TEVG pieces were immersed in Live/Dead working 
reagent prepared per the manufacturer’s instructions for 35 min at room temperature and 
imaged under red and green filters at 100X magnification. The remainder of the TEVGs 
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left were cut in half. One half from each was immersed in 10% formalin for histological 
analysis, prepared as in 3.2.4 and the other half was fixed in Karnovsky’s Fixative for 24 
hours for scanning electron microscopy (SEM). Karnovsky’s Fixative was prepared by 
dissolving 0.1M Cacodylic Acid (Omni Pur), adjusting the pH to 7.4, then adding 2.5% 
Glutaraldehyde (Polysciences) and 2.0% Formaldehyde (VWR). Samples were then 
dehydrated in one change each of 50%, 70%, 85%, and 95% Ethanol Solution (200 proof 
anhydrous Ethanol, Acros Organics, in ddH2O) for 20 min each, then two changes of 100% 
Ethanol (200 proof anhydrous Ethanol, Acros Organics) for 30 min, followed by critical 
point drying in Hexamethyldisilizane (HDMS. Electron Microscopy) for 20 min. Samples 
were allowed to air dry, then were stored in a desiccator until further processing. 
 
5.2.5 Static Seeding of Decellularized Arterial Scaffolds 
Arterial scaffolds were neutralized and cannulated as in 5.2.2. The cannulated scaffolds 
were then filled with ~400 μL endothelial cell solution, prepared as in 5.2.2, and the ends 
were plugged with plug caps. Fibroblast solution, prepared as in 5.2.2 was pipetted onto 
the scaffolds with a sterile transfer pipette, ~500 μL. The scaffolds were incubated at 37°C 
with 5% CO2 for 15 min. The scaffolds were rotated ~60°, seeded with more fibroblast 
solution, and incubated 15 more min. This was repeated a third time, then the scaffolds 
were incubated for 4 hours before being immersed in DMEM + 10% FBS + 1% Pen/Strep 
and incubated overnight. Normal and high glucose vascular bioreactors were set up as in 
5.2.3 and the samples were processed as in 5.2.4. 
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To analyze protein expression in the drop-seeded TEVGs, the snap-frozen samples were 
homogenized in 600 μL RIPA Buffer with a rotary-tip homogenizer for ~5 min. The 
homogenates were then centrifuged at 12,000 xg for 15 min at 4°C and the supernatants 
were transferred and stored at -20°C until further processing. Protein concentration was 
measured by BCA Assay and protein expression was measured by Western Blot using the 
method described in 4.2.3.1. 
 
To analyze cellularity, scaffold pieces were prepared for Live/Dead Cell Viability Assay 
for fixed and dehydrated for SEM. Dehydrated and desiccated samples were fixed to 
aluminum stubs using double-sided carbon tape. The stubs were sputter-coated with 
platinum at 10 V, 15 mA for 2 min on a Hummer® 6.2 Sputtering System (Anatech, Ltd.). 
Images were acquired on an S-4800 Scanning Electron Microscope (Kawasaki) at 5 kV 
and 1000X and 2500X magnification. 
 
5.3 Results and Discussion 
5.3.1 Analysis of Cellularity of Dynamically-Seeded Scaffolds 
The drop-seeded scaffolds had very few cells anywhere on the pieces imaged after 
Live/Dead Assay (Figure 5.5). Histology using DAPI and H&E (results not shown) 
showed similar results. Similarly protein and RNA concentrations were too low to perform 
protein and mRNA expression analysis by Western Blot and RT PCR, respectively (results 
not shown). It is for this reason that the bioreactor experiment was repeated using the 
simplified seeding technique. Complications with the rotary seeding chambers may have 
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contributed to a lack of cells on the scaffolds prior to subjecting them to flow in the 
bioreactor, but experimental complications prevented examination of the scaffolds prior to 
starting the bioreactor.  
 
 
Figure 5.5: Live/Dead Cell Viability Assay of Dynamically-Seeded TEVG after Bioreactor 
Conditioning. Rings of the seeded scaffolds were cut from three scaffolds each from each bioreactor (normal 
and high glucose), cut to lie flat, and immersed in Live-Dead solution for 35 min. The scaffold pieces were 
placed between two slides and imaged through the thickness of the arterial scaffold wall. A, B, and C are 
samples taken from three different scaffolds conditioned in normal media. D, E, and F are samples taken 
three different scaffolds conditioned in diabetic media. 
 
5.3.2 Analysis of Cellularity of Statically-Seeded Scaffolds 
Analysis of cell viability by Live/Dead Assay on seeded scaffolds prior to starting the 
bioreactor failed to produce images. Rings were cut from the middle of the scaffold, then 
those rings were cut to lie the piece flat so that the scaffold lumen was facing up. The 
seeded scaffold piece was then placed between two slides to keep the piece flat. However, 
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this method blurred any signal produced by fluorescing cells. Gross manipulation of the 
scaffold while under filtered fluorescent light showed cell attachment on the scaffold, but 
images could not be taken. Live/Dead imaging following bioreactor conditioning (Figure 
5.6) showed that cells were indeed retained, but coverage was inconsistent (Figure 5.7) 
and there was not a confluent layer of endothelial cells on the luminal surface, as would be 
required to create a totally non-thrombogenic surface. Further, retained fibroblasts were 
not observed on the statically-seeded scaffolds. 
 
 
Figure 5.6: Live/Dead Cell Viability Assay of Statically-Seeded TEVG after Bioreactor Conditioning. 
Rings of the seeded scaffolds were cut and immersed in Live-Dead solution for 35 min. The rings were 
removed from the solution and placed on their side on a glass histology slide. Images are taken from above 
the ring. The middle portion of the image shows the luminal side of the scaffold. The left (A, D, E, and F), 
upper (B), or upper right (C) shows the adventitial side of the scaffold from above. A, B, and C are samples 
taken from three different scaffolds conditioned in normal media. D, E, and F are samples taken three 
different scaffolds conditioned in diabetic media. 
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Figure 5.7: Scanning Electron Micrographs of Statically-Seeded TEVG after Bioreactor Conditioning 
 
5.3.3 Analysis of Protein Expression 
Tissue homogenates contained sufficient amounts of protein to assay by Western Blot; 
however, no identifiable bands were present on blots for PPARγ, NFκB, or NOX1 (Figures 
A2, A3, and A4). mTOR was upregulated in diabetic conditions (Figure 5.7, 1.3-fold 
greater expression), but not as much as in cultured hAEC for one week in diabetic 
conditions (3.8-fold greater expression). 
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Figure 5.8: Expression of mTOR in Statically-Seeded TEVG in Normal and High Glucose Media after 
Bioreactor Conditioning. Bands correspond to a Mw of 250 kDa, the expected mass of the detected protein. 
Exposure to diabetic conditions resulted in a 1.3-fold increase in mTOR expression. N=2 for each group and 
15 μg protein were used per lane 
 
5.4 Conclusions 
Achieving a confluent layer of endothelial cells has been one of the grand challenges in the 
field of vascular tissue engineering. Among these challenges is adherence of seeded cells 
to the scaffold. A vascular seeding chamber was used in these studies was used, but had 
some design flaws. First, the material was 3D-printed, a platform that offers low cost and 
easy of low-quantity manufacturing. However, the material has not held up with use and 
warping has caused the seal to be compromised. It can hold liquid, but it slowly leaks 
uncontrollably. It is the opinion of this author that enough media was lost during seeding 
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that cells may have starved and died before being placed in the bioreactor. Further, the 
design makes handling the chamber with sterile-gloved hands without compromising 
sterility technically challenging, and thus the opportunity to assess cell coverage on the 
scaffolds prior to bioreactor conditioning. 
 
Because of the lack of cells on TEVG seeded using the seeding chambers, a simplified 
method for seeding was used. While not sophisticated or well controlled, this method did 
achieve moderation endothelialization, but did not achieve a confluent layer. This however, 
did demonstrate the potential of cells to adhere to this scaffold, and to remain adhered and 
viable under shear stress for an extended period. The small amount of cells did cause 
difficulty in protein expression analysis, however. Only expression of mTOR was apparent 
via Western Blot. The scaffolds were a small enough size and the relatively small amount 
of cells meant that troubleshooting and repeat experiments were impossible without simply 
having more samples. Curiously though, mTOR expression was increased diabetic 
conditions, a result that confirms what was observed 2D culture of endothelial cells in 
Chapter 4.  
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK 
 
6.1 Conclusions 
A decellularized and PGG-stabilized vascular grafts was successfully developed. This graft 
is free from cells, as assessed by histological analysis, and cellular debris, as assessed by 
DNA content of the scaffolds. Next, the potential for endothelial-differentiated adipose 
derived stem cells to resist diabetic conditions was assessed. Differentiated ADSCs showed 
weak, but noticeable expression of endothelial markers, and show similar trends in 
expression to endothelial cells in normal versus diabetic conditions. This pilot study 
demonstrates efficacy of the differentiation protocol and a promise that differentiated 
ADSCs can perform well in a diabetic environment. Control of inflammation is an 
important problem in cardiovascular tissue engineering, so results such as these merit 
further investigation. Lastly, scaffolds were successfully seeded and retained cells after 
exposure to shear force in a bioreactor. Insufficient endothelialization is a persistent 
problem and perhaps the most important parameter to overcome in the field of tissue 
engineering, and while there was insufficient cell coverage to consider the grafts non-
thrombogenic, this is a step in the right direction. 
 
6.2 Recommendations for Future Work 
Preliminary results suggest that differentiated ADSCs can mitigate transcription of 
inflammatory cytokines in diabetic conditions. Further cell studies should be conducted to 
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the degree of response in diabetic conditions. Although the glucose concentration was high, 
one week may be insufficient to see a wide array of effects from hyperglycemia. Cells 
should be cultured for 2 and 4 weeks with greater numbers of cells, then assayed to 
determine the longer term response of differentiated ADSCs to diabetic conditions. 
 
One of the key hindrances in the seeding methodology is in the use of seeding chambers. 
3-D printed materials have poor mechanical strength and fatigue quickly. Further, 
disassembly of chambers to transfer the seeded scaffolds to the bioreactor complicates an 
already delicate procedure. I would suggest developing a seeding chamber that can have 
duel functionality as a bioreactor. This could function as a mix in the design of the current 
bioreactor and other small bioreactors, such as the 3DKube® sold by Kiyatec, Inc. Such a 
seeding chamber could house a single (or multiple in the case of renal branches) arterial 
scaffold that could then be attached to the existing bioreactor setup without need to transfer 
the arteries from one chamber to another. Further, this would allow for easier upscale of 
studies, which is a limiting factor in the current bioreactor design. 
 
Finally, a subsequent bioreactor study should be performed using growth factor-
differentiated ADSCs. The scaffolds should be seeded in the same manner as endothelial 
cells and fibroblasts and conditioned for 4 weeks in normal or high glucose. The seeded 
scaffolds should then be assayed for the same metabolic and inflammatory markers as 
endothelial cell and fibroblast-seeded scaffolds to determine the 3D in vitro resistance of 
ADSC-seeded scaffolds to damage caused by diabetic inflammation. 
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APPENDICES 
Appendix A - Supplementary Figures 
 
Figure A1: Western Blot for mTOR. Lane 1 = Ladder; Lane 2 = Differentiated hADSC in normal glucose 
media; Lane 3 = Differentiated hADSC in high glucose media; Lane 4 = hAEC in high glucose media; Lane 
5 = hAEC in normal glucose media; Lane 6 and 7 = Statically-seeded scaffolds conditioned in normal glucose 
media in vascular bioreactor; Lane 8 and 9 = Statically-seeded scaffolds conditioned in high glucose media 
in vascular bioreactor; N=3, pooled for Lanes 2-5; N=1 for Lanes 6-9; 15 μg protein per lane 
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Figure A2: Western Blot for NFκB. Lane 1 = Ladder; Lane 2 = Differentiated hADSC in normal glucose 
media; Lane 3 = Differentiated hADSC in high glucose media; Lane 4 = hAEC in high glucose media; Lane 
5 = hAEC in normal glucose media; Lane 6 and 7 = Statically-seeded scaffolds conditioned in normal glucose 
media in vascular bioreactor; Lane 8 and 9 = Statically-seeded scaffolds conditioned in high glucose media 
in vascular bioreactor; N=3, pooled for Lanes 2-5; N=1 for Lanes 6-9; 15 μg protein per lane 
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Figure A3: Western Blot for NOX1. Lane 1 = Ladder; Lane 2 = Differentiated hADSC in normal glucose 
media; Lane 3 = Differentiated hADSC in high glucose media; Lane 4 = hAEC in high glucose media; Lane 
5 = hAEC in normal glucose media; Lane 6 and 7 = Statically-seeded scaffolds conditioned in normal glucose 
media in vascular bioreactor; Lane 8 and 9 = Statically-seeded scaffolds conditioned in high glucose media 
in vascular bioreactor; N=3, pooled for Lanes 2-5; N=1 for Lanes 6-9; 15 μg protein per lane 
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Figure A4: Western Blot for PPARγ. Lane 1 = Ladder; Lane 2 = Differentiated hADSC in normal glucose 
media; Lane 3 = Differentiated hADSC in high glucose media; Lane 4 = hAEC in high glucose media; Lane 
5 = hAEC in normal glucose media; Lane 6 and 7 = Statically-seeded scaffolds conditioned in normal glucose 
media in vascular bioreactor; Lane 8 and 9 = Statically-seeded scaffolds conditioned in high glucose media 
in vascular bioreactor; N=3, pooled for Lanes 2-5; N=1 for Lanes 6-9; 15 μg protein per lane 
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Appendix B - Supplementary Tables 
 
Table A1: Protein Concentration of Cell and Tissue Lysates. For Western Blots, 5 μg of each sample 
was pooled for each lane. 
 
 
Concentration
(μg/μL)
A1NP 1.319
A2NP 1.319
A3NP 1.395
A1DP 2.269
A2DP 1.877
A3DP 1.395
E1NP 1.299
E2NP 2.561
E3NP 1.683
E1DP 3.459
E2DP 3.701
E3DP 3.632
Sample Conditions Sample
Differentiated ADSC in 
Normal Glucose Media
Differentiated ADSC in 
High Glucose Media
Endothelial Cells in 
Normal Glucose Media
Endothelial Cells in 
High Glucose Media
